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We aimed to investigate the molecular mechanisms
underlying the renal wasting of Naþ , Kþ , Ca2þ , and Mg2þ in
gentamicin (GM)-treated rats. Male Wistar rats were injected
with GM (40 or 80 mg/kg/day for 7 days, respectively; GM-40
or GM-80). The expression of NHE3, Na–K-ATPase, NKCC2,
ROMK, NCC, a-, b- and c-ENaC, and CaSR was examined in the
kidney by immunoblotting and immunohistochemistry.
Urinary fractional excretion of Naþ , Kþ , Ca2þ , and Mg2þ
was increased and urinary concentration was decreased in
both GM-40 and GM-80 rats. In cortex and outer stripe of
outer medulla (cortex) in GM-80 rats, the expression of NHE3,
Na–K-ATPase, and NKCC2 was decreased; NCC expression
was unchanged; and CaSR was upregulated compared to
controls. In the inner stripe of outer medulla (ISOM) in GM-80
rats, NKCC2 and Na–K-ATPase expression was decreased,
whereas CaSR was upregulated, and NHE3 and ROMK
expression remained unchanged. In GM-40 rats, NKCC2
expression was decreased in the cortex and ISOM, whereas
NHE3, Na–K-ATPase, CaSR, ROMK, and NCC abundance was
unchanged in both cortex and ISOM. Immunoperoxidase
labeling confirmed decreased expression of NKCC2 in the
thick ascending limb (TAL) in both GM-80- and GM-40-
treated rats. Immunoblotting and immunohistochemical
analysis revealed increased expression of a-, b-, and c-ENaC in
cortex in GM-80 rats, but not in GM-40 rats. These findings
suggest that the decrease in NKCC2 in TAL seen in response
to low-dose (40 mg/kg/day) gentamicin treatment may play
an essential role for the increased urinary excretion of Mg2þ
and Ca2þ , and play a significant role for the development of
the urinary concentrating defect, and increased urinary
excretion of Naþ and Kþ . At high-dose gentamicin, both
proximal and TAL sodium transporter downregulation is
likely to contribute to this.
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Aminoglycoside antibiotics (AGAs) have been widely used
clinically because of high efficacy and of low costs. AGAs,
which include gentamicin, are used in the treatment of severe
bacterial infections of the abdomen and urinary tract;
however, serious problems and therefore dose-limiting
factors are the side effects of nephrotoxicity and ototoxicity
with an incidence up to 20% of patients undergoing
treatment.1,2 AGAs are low-protein binding drugs (o10%)
and freely filtered through the glomerulus3 without being
metabolized in the body. About 10% of the parenterally
administered drug accumulates in the renal cortex, leading
to renal proximal tubule (PT) damage, including struc-
tural changes and functional impairment of the plasma
membrane, mitochondria, and lysosomes.4 After glomerular
filtration, aminoglycosides are selectively retained in the
epithelial cells of the PTs, specifically the S1 and S2 segments
of the PT, but not in the distal parts of the nephron.5,6
Aminoglycoside-induced nephrotoxicity manifests clini-
cally by nonoliguric renal failure with a progressive increase
in serum creatinine levels and a decrease in urinary
concentration after several days of administration. Moreover,
AGAs can cause aminoaciduria, glucosuria, and increased
urinary excretion of sodium, potassium, magnesium, and
calcium.7 In particular, dose-dependent hypermagnesiuria is
known to occur soon after start of therapy and is reversible
on discontinuation.7,8 However, the underlying molecular
mechanisms leading to renal wasting of sodium, potassium,
magnesium, and calcium in response to gentamicin treat-
ment are still undefined.
The main site for renal tubular sodium reabsorption is the
PT, reabsorbing approximately two-thirds of the filtered
sodium load. In this tubular segment, the type 3 Naþ /Hþ
exchanger (NHE3) is mainly responsible for apical sodium
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reabsorption,9 and the type 2 Na-Pi cotransporter is also
involved.10,11 As in all renal tubule segments, the Na-K-
ATPase is strongly expressed in the basolateral membrane12
playing a crucial role for sodium reabsorption along the
nephron. In the thick ascending limb (TAL), the bumetanide-
sensitive Na–K–2Cl cotransporter (NKCC2),13–15 NHE3 and
Na–K-ATPase are the key sodium transporters for active
sodium reabsorption. Potassium ions recirculate into the
tubular lumen via the apical potassium channel Kir 1.1
(ROMK),16,17 whereas chloride is reabsorbed basolaterally
through ClC-Kb chloride channels.18 Thus, NKCC2, ROMK,
ClC-Kb, and Na-K-ATPase provide a lumen-positive trans-
epithelial voltage in the TAL, which enhances magnesium and
calcium reabsorption in this segment. In the distal convoluted
tubule, the thiazide-sensitive Na–Cl cotransporter (NCC) is
responsible for apical sodium reabsorption.19,20 In the
collecting duct, electrogenic entry of sodium from the lumen
into the cells is mediated by ENaC located in the apical plasma
membrane.21 On the basolateral side, Na-K-ATPase transports
sodium out of the cell into the extracellular interstitium and
provides the driving force for sodium reabsorption. In rat
kidney, three homologous subunits (a, b, and g) contributing
to the functional ENaC protein22 are present in the late distal
convoluted tubule, connecting tubule (CNT), cortical (CCD),
and outer medullary collecting duct (OMCD), and to a lesser
extent, in the inner medullary collecting duct.23,24
The kidney plays a key role in maintaining magnesium
homeostasis. In the TAL, the main site of magnesium
reabsorption along the nephron (reabsorbing approximately
70% of the filtered magnesium load), magnesium transport is
passively driven by the lumen-positive voltage. Together with
calcium, magnesium is reabsorbed paracellularly through the
tight-junction protein paracellin-1.25
AGAs, which include gentamicin, function as polyvalent
cations and activate the calcium sensing receptor (CaSR).26
The CaSR is a large glycoprotein belonging to the superfamily
of G protein-coupled receptors. In the TAL, the CaSR is
highly expressed basolaterally,27 sensing extracellular calcium,
magnesium and other polyvalent cations, including AGAs.
The localization of the CaSR in the kidney thus suggests that
it may influence magnesium and calcium homeostasis by
directly regulating renal magnesium and calcium reabsorp-
tion and excretion. In addition, there is evidence for a
connection between divalent cation and water (and sodium)
metabolism. Activation of the CaSR could impair sodium
chloride and water reabsorption in the TAL and collecting
duct by inhibition of hormone-stimulated cyclic adenosine
30,50 monophosphate (cAMP) formation and/or other
calcium-dependent signaling mechanisms.28,29
The purposes of our present study were to identify the
molecular mechanisms underlying the decreased urinary
concentration and renal wasting of sodium, magnesium, and
calcium associated with gentamicin-treatment. In particular,
we test the hypothesis that gentamicin treatment induces
downregulation of NKCC2, which in turn will reduce the
lumen-positive transepithelial voltage in the TAL, leading to
impaired passive paracellular reabsorption of magnesium and
calcium in this part of the nephron. This hypothesis is
consistent with the clinically and experimentally observed
renal waste of magnesium and calcium in response to
furosemide treatment.30 To address this hypothesis, two
protocols were used. In one protocol, a relatively high dose of
gentamicin was used (80 mg/kg/day) known to be associated
with PT defects evidenced by glucosuria. In the second
protocol a moderate dose of gentamicin was used (40 mg/kg/
day) which is known not to be associated with glucosuria but
still leads to increased urinary excretion of Naþ , Kþ , Ca2þ ,
and Mg2þ and urinary concentrating defects (both proto-
cols). Specifically, we examined (1) whether there were
changes in the abundance of the major renal sodium
transporters along the nephron and collecting duct, that is,
NKCC2, NHE3, Na–K-ATPase, NCC, and all ENaC subunits;
(2) whether there were changes in the abundance of the
ROMK and the calcium-sensing receptor, particularly in
the TAL; and (3) whether these changes were associated
with changes in urinary sodium, magnesium and calcium
excretion, and urine concentration.
RESULTS
Gentamicin treatment decreases urinary concentration
and increases urinary excretion of sodium, potassium,
magnesium, and calcium
In both protocols (protocol 1, gentamicin 80 mg/kg/day and
protocol 2, gentamicin 40 mg/kg/day), all gentamicin-treated
rats exhibited significantly increased fractional excretions
of sodium, potassium, magnesium, and calcium (Tables 1
and 2). Moreover, gentamicin-treated rats in both protocols
demonstrated increased urine output and decreased urine
osmolality (Tables 1 and 2), indicating decreased urinary
concentration.
In protocol 1, at 24 h after the final injection of high-dose
gentamicin, plasma trough levels of gentamicin 40.5 mg/ml
were measured. Gentamicin-treated rats presented massive
glucosuria, whereas controls had no glucosuria. Rats treated
with 80 mg/kg/day gentamicin also had polyuric renal failure
with a threefold increase of plasma creatinine concentra-
tion along with significantly decreased renal creatinine
clearance. Table 1 summarizes the functional data from
protocol 1.
In protocol 2, there were no detectable plasma gentamicin
trough levels 24 h after the final injection of the lower dose
of gentamicin. Neither getamicin-treated nor control rats
in protocol 2 had glucosuria. The gentamicin-treated rats
exhibited significantly decreased creatinine clearance albeit at a
lesser extent compared with protocol 1, whereas plasma
creatinine levels were not significantly changed compared
to controls. Table 2 summarizes the functional data from
protocol 2.
Renal expression of NKCC2, NHE3, Na–K-ATPase, and NCC
We examined the renal abundance of the NKCC2 in
gentamicin-treated rats and controls using protein samples
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from the cortex or from the inner stripe of the outer medulla
(ISOM) for semiquantitative immunoblotting. In protocol 1,
NKCC2 expression of gentamicin-treated rats was signi-
ficantly reduced in cortex to 5177% of the control levels,
Po0.05 (Figure 1a and b, Table 3) and also in ISOM to
5777% of the control levels, Po0.01 (Figure 1c and d,
Table 3). Accordingly, in protocol 2, NKCC2 abundance was
decreased in cortex to 50710% of the control levels, Po0.05
(Figure 1e and f, Table 4), and in ISOM to 60710% of the
control levels, Po0.05 (Figure 1g and h, Table 4) in rats
treated with gentamicin.
Consistent with the immunoblotting data, immunohisto-
chemical analysis of paraffin-embedded kidney sections
revealed decreased immunoperoxidase labeling of NKCC2
in gentamicin-treated rats. In control rats (protocol 1),
abundant immunoperoxidase labeling of NKCC2 was asso-
ciated with apical plasma membrane domains of the cortical
TAL (arrows in Figure 2a) and in the ISOM, strong NKCC2
labeling was observed in the apical plasma membrane
domains of the medullary TAL (arrows in Figure 2c). In
contrast, in gentamicin-treated rats (80 mg/kg/day of genta-
micin) the labeling intensity of NKCC2 was markedly
reduced both in cortical and medullary TAL (arrows in
Figure 2b and d) as compared with controls (Figure 2a and
c). Moreover, in protocol 2 (40 mg/kg/day of gentamicin),
immunolabeling of NKCC2 was decreased in cortical and
medullary TAL of gentamicin-treated rats (arrows in Figure
2f and h) compared with controls (arrows in Figure 2e
and g).
Next, we investigated whether there were changes in
the protein expression of the Naþ /Hþ exchanger NHE3 in
cortex and ISOM. In protocol 1, semiquantitative immuno-
blotting revealed significant downregulation of NHE3 expres-
sion in cortex in gentamicin-treated rats to 5775% of the
control levels, Po0.01 (Figure 3a and b, Table 3), whereas the
abundance of NHE3 in ISOM was not altered compared to
controls (Table 3). In protocol 2, NHE3 protein abundance
was unchanged in cortex (Figure 3c and d, Table 4) and
ISOM (Table 4).
These findings were consistent with immunohisto-
chemical analysis. In protocol 1, in the kidney cortex of
control rats, immunoperoxidase labeling of NHE3 was
associated with apical domains of the PTs (arrow in Figure
4a) and cortical TAL (asterisk in Figure 4a). Immunohisto-
chemical analysis of the kidneys from gentamicin-treated
rats revealed decreased labeling intensity of NHE3 in the PT
(arrows in Figure 4b), whereas the labeling intensity was
unchanged in the cortical TAL (asterisks in Figure 4b). Light
microscopic examination demonstrated tubular damage and
cell death in gentamicin-treated rats (protocol 1). Tubular
necrosis was most pronounced in the convoluted parts of PT
(Figures 2b and 4b), whereas it was less severe in the straight
part of the PT (not shown). Necrotic cells were detached
from the tubular basement membrane and were seen in the
tubular lumen. Furthermore, disruption of the brush border
(P in Figure 4b) and focal loss of individual tubular cells in
the PT (P in Figure 4b) were also seen. In the ISOM of
kidneys from control rats, NHE3 labeling was observed in the
Table 1 | Functional parameters from protocol 1 (gentamicin
80 mg/kg/day)
GM (n=10) Control (n=7)
P-gentamicin trough level (mg/ml) 2.570.5** o0.5
U-Gluc-STIX (mmol/l) 22.272.3** negative
Ccr (ml/min) 0.470.05** 1.270.1
UO (ml/min) 14.471.7** 6.971
P-Osm (mosm/kg H2O) 31672.3** 30571.1
U-Osm (mosm/kg H2O) 864772** 20027300
P-Cr (mmol/l) 109.6712.2** 33.371.9
P-Na (mmol/l) 134.171.4 136.171.4
P-K (mmol/l) 4.370.1 4.070.2
P-Mg (mmol/l) 1.470.03** 1.170.05
P-total Ca (mmol/l) 2.770.02** 2.470.03
FE-Na (%) 1.870.2** 0.670.05
FE-K (%) 178.1719.9** 66.876.8
FE-Mg (%) 23.974.6** 0.770.1
FE-Ca (%) 8.870.9** 0.470.1
U-Na/K 0.2970.01 0.370.01
Ccr, creatinine clearance; FE-Ca, fractional excretion of calcium into urine; FE-K,
fractional excretion of potassium into urine; FE-Mg, fractional excretion of magne-
sium into urine; FE-Na, fractional excretion of sodium into urine; GM, gentamicin;
P-Cr, plasma creatinine; P-gentamicin trough level, plasma gentamicin level 24 h
after last injection; P-K, plasma potassium; P-Mg, plasma magnesium; P-Na, plasma
sodium; P-osm, plasma osmolality; P-total Ca, plasma total calcium; U-Gluc-STIX,
urine glucose measured by urine STIX; UO, urine output; U-osm, urine osmolality;
U-Na/K, urine Na/K ratio.
Values are expressed as mean7s.e. GM n=10, control n=7. These values are
measured at the last day of the experiment (day 7).
**Po0.01 compared with controls.
Table 2 | Functional parameters from protocol 2 (gentamicin
40 mg/kg/day)
GM (n=10) Control (n=7)
P-gentamicin trough level (mg/ml) o0.5 o0.5
U-Gluc-STIX (mmol/l) Negative Negative
Ccr (ml/min) 1.170.1** 1.470.04
UO (ml/min) 10.870.7** 7.270.7
P-Osm (mosm/kg H2O) 30371.4 30271.5
U-Osm (mosm/kg H2O) 1359785** 21037217
P-Cr (mmol/l) 33.773.8 24.470.6
P-Na (mmol/l) 135.970.4 135.370.6
P-K (mmol/l) 5.270.2** 6.370.2
P-Mg (mmol/l) 0.970.04 0.870.03
P-total Ca (mmol/l) 2.370.05 2.470.1
FE-Na (%) 0.870.06* 0.570.1
FE-K (%) 72.278.6** 29.876.1
FE-Mg (%) 15.471.1** 1.870.7
FE-Ca (%) 2.370.2** 0.770.2
U-Na/K 0.3770.02 0.3170.02
Ccr, creatinine clearance; FE-Ca, fractional excretion of calcium into urine; FE-K,
fractional excretion of potassium into urine; FE-Mg, fractional excretion of magne-
sium into urine; FE-Na, fractional excretion of sodium into urine; GM, gentamicin;
P-Cr, plasma creatinine; P-gentamicin trough level, plasma gentamicin level 24 h
after last injection; P-K, plasma potassium; P-Mg, plasma magnesium; P-Na, plasma
sodium; P-osm, plasma osmolality; P-total Ca, plasma total calcium; U-Gluc-STIX,
urine glucose measured by urine STIX; UO, urine output; U-osm, urine osmolality;
U-Na/K, urine Na/K ratio.
Values are expressed as mean7s.e. GM n=10, control n=7. These values are
measured at the last day of the experiment (day 7).
*Po0.05, **Po0.01 compared with controls.
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apical domains of the medullary TAL (T in Figure 4c) and
thin limb structures. The immunolabeling intensity in the
ISOM was unchanged in gentamicin-treated rats (Figure 4d)
compared to controls.
Immunoblotting of the a1-subunit of the Na-K-ATPase
in cortex and ISOM revealed significant reduction in the
expression in gentamicin-treated rats (protocol 1) to 6878%
of the control levels, Po0.05 (Figure 5a and b, Table 3) in
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Figure 1 | Semiquantitative immunoblots of kidney proteins prepared from cortex, and ISOM from control and gentamicin-treated
rats in protocol 1 (gentamicin 80 mg/kg/day) and protocol 2 (gentamicin 40 mg/kg/day). (a–d) In gentamicin-treated rats
(protocol 1), NKCC2 protein abundance was markedly decreased in cortex and ISOM compared to controls. (e–h) In gentamicin-treated rats
(protocol 2), NKCC2 protein abundance was significantly decreased in cortex and ISOM compared to control rats.
Table 3 | Densitometric analysis of protein expression in
protocol 1 (gentamicin 80 mg/kg/day)
GM (n=10) Control (n=7)
Cortex
NKCC2 5177* 100715
NHE3 3674** 10075
Na–K-ATPase 6878* 10078
NCC 88724 10078
CaSR 197725** 100713
a-ENaC 153714** 10078
b-ENaC 16478** 10074
g-ENaC 197711** 100720
ISOM
NKCC2 57710** 10079
NHE3 59710 100718
Na–K-ATPase 6677** 10075
ROMK 109715 10077
CaSR 160718* 100715
b-ENaC 179715** 10076
g-ENaC 15879** 10079
CaSR, calcium sensing receptor; GM, gentamicin; NCC, thiazide-sensitive Na–Cl
cotransporter; NHE3, type 3 Na/H exchanger; NKCC2, bumetanide-sensitive Na–K–2Cl
cotransporter.
Values are expressed as mean7s.e.
*Po0.05, **Po0.01 compared with controls.
Table 4 | Densitometric analysis of protein expression in
protocol 2 (gentamicin 40 mg/kg/day)
GM-II (n=10) Control (n=7)
Cortex
NKCC2 50710* 100719
NHE3 86713 10078
Na–K-ATPase 136720 10079
NCC 8975 10076
CaSR 10779 10075
a-ENaC 110716 100711
b-ENaC 129719 100718
g-ENaC 143724 100717
ISOM
NKCC2 60710* 100711
NHE3 87716 100726
Na–K-ATPase 9777 100712
ROMK 78723 100718
CaSR 9876 10074
b-ENaC 17379** 10076
g-ENaC 13177** 10076
CaSR, calcium sensing receptor; GM, gentamicin; NCC, thiazide-sensitive Na–Cl
cotransporter; NHE3, type 3 Na/H exchanger; NKCC2, bumetanide-sensitive Na–K–2Cl
cotransporter.
Values are expressed as mean7s.e.
*Po0.05, **Po0.01 compared with controls.
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cortex and 6677%, Po0.01 in ISOM (Figure 5c and d,
Table 3). In contrast, in protocol 2, the expression of the
a1-subunit of the Na–K-ATPase was not changed in cortex
(Figure 5e and f, Table 4) or in ISOM (Figure 5g and h,
Table 4).
Next, we examined the renal abundance of the NCC in
gentamicin-treated rats and controls. In protocol 1 (Table 3)
and protocol 2 (Table 4), NCC expression was unchanged in
rats receiving gentamicin injections compared with controls.
Renal expression of ROMK
In the ISOM, we determined ROMK protein abundance by
semiquantitative immunoblotting. ROMK expression was
unchanged in rats treated with gentamicin compared to
control rats in both protocol 1 (Table 3) and protocol 2
(Table 4).
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Figure 2 | Immunoperoxidase microscopy of NKCC2 in cTAL and
mTAL in protocol 1 (gentamicin 80 mg/kg/day) and protocol
2 (gentamicin 40 mg/kg/day). In response to gentamicin,
immunoperoxidase labeling of NKCC2 is decreased in cTAL (b
and f, arrows) compared to controls (a and e, arrows) and mTAL
(d and h, arrows) compared to controls (c and g, arrows). MD,
macula densa; G, glomerulus; asterisk indicates PT (panel b and f)
and arrows indicate NKCC2 labeling in cTAL and mTAL.
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Figure 3 | Semiquantitative immunoblots of kidney proteins
prepared from cortex from control and gentamicin-treated rats.
(a and b) In protocol 1 (gentamicin 80 mg/kg/day), NHE3 protein
abundance is reduced in response to gentamicin. (c and d) In
protocol 2 (gentamicin 40 mg/kg/day), NHE3 expression remains
unchanged.
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Figure 4 | Immunoperoxidase microscopy of NHE3 in PT, cTAL,
and mTAL in rats treated with 80 mg/kg/day gentamicin and
controls. In protocol 1, gentamicin treatment results in severe
alterations in the morphology of the proximal tubule (P in panel b),
as indicated by vacuolization and elimination of parts of the brush
border, along with decreased immunoperoxidase labeling of NHE3
(b, arrows) compared with controls (panel a, P, arrow). In cTAL (panels
a and b, asterisk), NHE3 immunolabeling remains unchanged. Also
in mTAL, NHE3 immunolabeling is unchanged (T in panels c and d).
MD, macula densa; G, glomerulus; P, proximal tubule; asterisk,
cTAL; arrowheads indicate NHE3 labeling in PT.
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Renal expression of CaSR
The protein abundance of the CaSR was determined in
cortex and ISOM from kidneys of gentamicin-treated or
control rats. In protocol 1, semiquantitative immunoblotting
revealed markedly increased CaSR expression in gentamicin-
treated rats to 197725% of the control levels in cortex,
Po0.01 (Figure 6a and b, Table 3), and also in ISOM
to 160718% compared with controls, Po0.05 (Table 3). In
contrast, in protocol 2, CaSR protein abundance was
unchanged in gentamicin-treated rats compared with con-
trols in cortex (Figure 6c and d, Table 4) and ISOM (Table 4).
Immunohistochemical analysis confirmed these results.
Immunoperoxidase labeling was associated with basolateral
domains in TAL (Figure 7a and b) and gentamicin treatment
(protocol 1) was associated with increased immunoperoxi-
dase labeling in cortical TAL (arrows in Figure 7b).
Renal expression of ENaC (a-, b-, and c-subunit)
In protocol 1, a-ENaC abundance in cortex was significantly
upregulated in gentamicin-treated rats to 153714% of the
control levels, Po0.01 (Figure 8a, Table 3). The b-ENaC-
subunit protein abundance in cortex was significantly
increased in response to gentamicin treatment to 16478%,
Po0.01 (Figure 8a, Table 3), as well as in ISOM to 1797
15%, Po0.01 (Table 3). Finally, also g-ENaC expression in
cortex (85 kDa band) was markedly increased in gentamicin-
treated rats to 197711%, Po0.01 (Figure 8a, Table 3) and
the 70 kDa band was invisible. Moreover, in ISOM, g-ENaC
expression (85 kDa band) was significantly increased in
gentamicin-treated rats to 15879% of the control levels,
Po0.01 (Table 3), and the 70 kDa band was nearly invisible.
In protocol 2, there was no difference in a-ENaC
expression in cortex between the gentamicin-treated group
and the control group (Figure 8b, Table 4). Moreover, the
abundance of b-ENaC and g-ENaC was unchanged in cortex
in gentamicin-treated rats compared with controls (Figure
8b, Table 4), whereas a significant increase was noted in
ISOM of kidneys from gentamicin-treated rats for both
b-ENaC (17379%, Po0.01, Table 4) and g-ENaC (1317
7%, Po0.01, Table 4).
Immunohistochemical analysis of b-ENaC in protocol 1
revealed increased immunoperoxidase labeling in CNT, CCD,
and OMCD in response to gentamicin treatment compared
with controls (data not shown). In parallel, immuno-
peroxidase labeling of g-ENaC in protocol 1 was more
intense in CNT, CCD (Figure 9a–d), and OMCD (not shown)
compared with controls.
DISCUSSION
In the present study, we demonstrated that gentamicin
treatment of rats was associated with increased urinary
excretion of sodium, potassium, magnesium, and calcium.
Moreover, urinary concentration ability was significantly
decreased in response to gentamicin treatment. Light
microscopic examination demonstrated severe PT damage
and cell death in gentamicin-treated rats in protocol 1
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
Na-K-ATPase (ISOM)Na-K-ATPase (cortex)
b
a
d
c
h
g
**
Control GM: 80 mg/kg/day
1 2 3 4 5 6 7 1 2 3 4 5 6 7
Control GM: 80 mg/kg/day
1 2 3 4 5 6 7 1 2 3 4 5 6 7
1 2 3 4 5 6 7 1 2 3 4 5 6 7
f
e
Control GM: 40 mg/kg/day
1 2 3 4 5 6 7 1 2 3 4 5 6 7
*
- 96
  kDa
Control GM: 40 mg/kg/day
- 96
  kDa
n = 7 n = 7
n = 7 n = 7 n = 7 n = 7
Na-K-ATPase (cortex) Na-K-ATPase (ISOM)
n = 7 n = 7
 1
-
N
a-
K-
AT
Pa
se
e
xp
re
ss
io
n
(fr
ac
tio
n o
f c
on
tro
l)
 1
-
N
a-
K-
AT
Pa
se
e
xp
re
ss
io
n
(fr
ac
tio
n o
f c
on
tro
l)
 1
-
N
a-
K-
AT
Pa
se
e
xp
re
ss
io
n
(fr
ac
tio
n o
f c
on
tro
l)
 1
-
N
a-
K-
AT
Pa
se
e
xp
re
ss
io
n
(fr
ac
tio
n o
f c
on
tro
l)
- 96
  kDa
- 96
  kDa
Figure 5 | Semiquantitative immunoblots of kidney proteins prepared from cortex, and inner stripe of outer medulla (ISOM) from
control and gentamicin-treated rats. In protocol 1, 80 mg/kg/day gentamicin treatment leads to decreased Na-K-ATPase protein abundance
in (a and b) cortex and (c and d) ISOM compared to controls. In protocol 2 (gentamicin 40 mg/kg/day), Na–K-ATPase expression was unchanged
in (e and f) cortex and (g and h) ISOM.
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(80 mg/kg/day gentamicin) and the rats also developed
glucosuria, consistent with previous studies. This was consis-
tent with the observed decrease in the abundance of PT
sodium transporters (NHE3, Na–K-ATPase). This was not
seen by treatment with a relatively low dose of gentamicin
(40 mg/kg/day). In high-dose gentamicin treatment the expres-
sions of several TAL sodium transporters were reduced,
whereas in low-dose gentamicin treatment NKCC2 abundance
was selectively decreased. ENaC subunit expression was either
unchanged or increased likely to represent a compensatory
process. In conclusion, the decreased NKCC2 expression in the
TAL is likely to contribute significantly to the urinary concen-
trating defect by impairing the generation of the hypertonic
medullary interstitium. Importantly, this NKCC2 downregula-
tion may also contribute significantly to the increased urinary
magnesium and calcium excretion by decreasing the lumen-
positive voltage. Also, the decreased abundance of PT sodium
transporters and NKCC2 may contribute to the increased
urinary sodium excretion. These conclusions will be discussed
in detail in the followings.
Increased urinary excretion of sodium, potassium,
magnesium, and calcium in response to gentamicin
treatment in rats
Gentamicin-treated rats in both protocols presented with
increased urinary excretion of sodium, potassium, magne-
sium, and calcium. We estimated this by increased fractional
excretion of sodium, potassium, magnesium, and calcium.
Consistent with this, it is well known that hypermagnesiuria
seen in response to treatment with AGAs is always associated
with hypercalciuria.31,32 This suggests that AGAs inhibit renal
tubular reabsorption of these two polyvalent cations in the
TAL, where the filtered magnesium and calcium are mainly
reabsorbed, and/or in the distal convoluted tubule.33 We
hypothesize that the decrease in the expression of NKCC2
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Figure 6 | Semiquantitative immunoblots of kidney proteins
prepared from cortex from control and gentamicin-treated rats.
In rats treated with 80 mg/kg/day gentamicin (protocol 1), CaSR
protein abundance was increased in (a and b) cortex, but
remained unchanged in (c and d) cortex in protocol 2, gentamicin
40 mg/kg/day.
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Figure 7 | Immunoperoxidase microscopy of CaSR in cTAL in
kidneys from rats treated with 80 mg/kg/day gentamicin or
controls. In response to gentamicin immunoperoxidase labeling
of CaSR is increased (b, arrows) compared to controls (a, arrows).
G, glomerulus; asterisk indicates PT and arrows indicate CaSR
labeling in cTAL.
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Figure 8 | Semiquantitative immunoblots of kidney proteins
prepared from cortex from control and gentamicin-treated rats.
(a) In protocol 1 (gentamicin 80 mg/kg/day), a-, b-, and g-ENaC
expression was significantly increased in gentamicin-treated rats.
However, the 70 kDa band of g-ENaC is nearly invisible, indicating low
aldosterone activity. (b) In protocol 2 (gentamicin 40 mg/kg/day),
a-, b-, and g-ENaC expression was unchanged.
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in TAL observed in gentamicin-treated rats may contribute to
this, as this would lead to decreased sodium reabsorption in
TAL and subsequently reduced lumen-positive voltage, as
discussed below. Many studies have shown that renal wasting
of magnesium, in addition to sodium, potassium, calcium,
and phosphate wasting, occurs even by use of gentamicin in
therapeutic doses, and is seen immediately after the infusion
of the drug, and long before other evidence of renal
dysfunction or structural injury develops.8,34–36
Dysregulation of renal sodium transporters and CaSR in TAL
We demonstrated that treatment with relatively high doses
of gentamicin (protocol 1) was associated with significantly
decreased protein abundance of NKCC2 and Na–K-ATPase in
the TAL, whereas NHE3 and ROMK abundance was
unchanged. In contrast, treatment with relatively low doses
of gentamicin (protocol 2) was associated with selectively
decreased abundance of NKCC2 in the TAL, but unchanged
abundance of NHE3, Na–K-ATPase, and ROMK. As all
gentamicin-treated rats in both protocols demonstrated
significantly increased urinary excretion of sodium, it is
therefore likely that the downregulation of NKCC2 may play
a significant role in the decreased TAL sodium reabsorption
and increased urinary excretion of sodium. Moreover,
reabsorption of magnesium and calcium in the TAL may be
decreased by impaired TAL sodium reabsorption resulting in
a decreased lumen-positive voltage, and hence increased
urinary magnesium and calcium excretion.
Activation of the CaSR has been shown to lead to an
inhibition of passive reabsorption of magnesium and calcium
in the TAL and reduced active transport in the distal
convoluted tubule.37–40 In addition, previous studies also
indicate that activation of the CaSR increases both NaCl and
calcium excretion in rats and humans.39,41 The observed
upregulation of the CaSR in rats treated with higher dose of
gentamicin (protocol 1, 80 mg/kg/day) would be consistent
with a role for the CaSR in mediating a decrease in
NaCl reabsorption in the TAL and consequently a reduced
reabsorption of divalent cations. Along with this view,
we have previously demonstrated that CaSR expression was
increased in experimentally induced hypercalcemia asso-
ciated with decreased NaCl reabsorption and downregulation
of NKCC2.42 In agreement with the observed upregulation of
CaSR in gentamicin-treated rats, previous studies have
demonstrated that AGAs, which include gentamicin, have
been shown to function as polyvalent cations activating
the CaSR.26
Together with these previous findings, our results are
consistent with the hypothesis that activation of the CaSR
(e.g. viz. an increased expression) reduces the rate of sodium
reabsorption in the TAL, thus decreasing the lumen-positive
voltage. As the latter is the driving force for paracellular
divalent cation transport in this nephron segment, this would
consequently impair magnesium and calcium reabsorption.43
Consistent with this, the use of loop diuretics causes renal
wasting of magnesium and calcium associated with natri-
uresis. To date at least two second messenger system that can
be activated by the CaSR are known to be involved in
affecting sodium chloride transport in the TAL: (1) reduction
of cellular cAMP and (2) activation of P450 and subsequent
generation of 20-HETE.44 In the TAL, NaCl, magnesium, and
calcium reabsorption is likely to be cAMP-dependent. Thus,
hormones that are known to increase cellular cAMP levels
(e.g. AVP, PTH, glucagon, and calcitonin) increase NaCl,
magnesium, and calcium reabsorption in the TAL.45 Treat-
ment with DDAVP (a vasopressin V2-selective agonist)
upregulates NKCC2 expression.46,47 The V2 receptor is linked
to adenyl cyclase activation, and thus the increase of NKCC2
abundance by vasopressin might result from cAMP genera-
tion. Hence, in murine SLC12A1 (mouse NKCC2 gene)
a cAMP-regulatory element was identified.48 In addition,
20-HETE is known to inhibit NKCC2,49 apical potassium
recycling channels50 and Na-K-ATPase,51 thereby reducing
sodium chloride reabsorption in the TAL. As an extension of
these observations, patients with very potent activating
mutations in the CaSR gene (causing autosomal dominant
hypocalcemia, OMIM þ 601199) developed a Bartter-like
phenotype. In addition to hypomagnesemia and hypocalce-
mia, these patients presented with renal salt and water loss
associated with hypokalemic alkalosis.52,53
In protocol 1 and protocol 2, b- and g-ENaC protein
abundance was increased in ISOM. This is likely to reflect
a compensatory effect in response to the decreased sodium
reabsorption in the PT and TAL segments. How-
ever, unchanged urinary Na/K ratio54 and unchanged NCC
expression20 indicate that the aldosterone-receptor was not
activated in the animal models. Thus, further studies are
needed to identify the underlying mechanisms for the
observed changes of ENaC protein abundance.
CT
N
CC
D
Control GM
a b
c d
80 mg/kg/day
80 mg/kg/day
Figure 9 | Immunoperoxidase microscopy of c-ENaC in the
connecting tubule (CNT) and cortical collecting duct (CCD) in
protocol 1. In rats treated with 80 mg/kg/day gentamicin, g-ENaC
immunoperoxidase labeling was increased in CNT (b, arrows)
compared with controls (a, arrows) and CCD (d, arrows) compared
with controls (c, arrows).
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Decreased urinary concentration in gentamicin-treated rats
Decreased urinary concentration was observed in response to
gentamicin treatment. A previous study indicates that
gentamicin treatment of rats reduces the expression of
collecting duct AQP2 and AQP3 expression in rat kidney.55
Interestingly, this study demonstrated that cAMP generation
in response to AVP was decreased, but not in response to
forskolin, suggesting that the primary impairment in the
pathway of cAMP formation lies at the G protein level. In
accordance with this gentamicin has been shown to impair
cAMP generation in outer medullary TAL and collecting
duct.56 Whether such an inhibition could be potentially
involved in the downregulation of NKCC2 remains to be
demonstrated. However, it is likely that a downregulation of
NKCC2 may reduce sodium chloride reabsorption in the TAL
leading to a reduced countercurrent multiplication, and thus
impair generation of hyperosmolar interstitium and urine
concentration.
Dysregulation of renal sodium transporters and CaSR in
cortex
Gentamicin is reabsorbed exclusively in the PT and
accumulates in the renal cortex. In protocol 1, where rats
received a higher dosage of gentamicin, expression of the PT
sodium transporters, that is, NHE3, and Na-K-ATPase, and
also NKCC2 were changed as determined by immunoblotting
and in immunohistochemical analysis. Immunoperoxidase
microscopy revealed that NHE3 expression was only
decreased in the PT but unchanged in cortical TAL. Together
with the significant glucosuria exclusively observed in rats
treated with a higher dose of gentamicin, this indicates severe
PT damage and suggests that this is very likely to be the
reason for reduced NHE3 expression in the PT. In protocol 2,
where rats received a lower dose of gentamicin, NKCC2
expression was selectively decreased in cortex observed by
both immunoblotting and immunohistochemistry. NHE3
and Na–K-ATPase protein abundance remained unchanged.
In both protocols NCC expression was not changed, which
is consistent with the previous functional data revealing
absence of enhanced aldosterone action.20 Moreover, in both
protocols the urinary Na/K ratio was unchanged in rats
receiving gentamicin compared to controls, which indicates
that the aldosterone-receptor was not activated in the
aldosterone-sensitive nephron segments. The results obtained
regarding ENaC also support this view. Only in protocol 1,
a-, b-, and g-ENaC protein abundance was increased in
contrast to protocol 2. The g-ENaC 70 kDa band was nearly
invisible, again indicating no increased aldosterone activity.
The mechanisms underlying the increased ENaC expression
are not clear.
CaSR protein abundance was increased in protocol 1,
which might result from strong activation by gentamicin. The
CaSR might play a role in impaired NKCC2 and Na–K-
ATPase expression and NaCl reabsorption in the cortical
TAL, followed by altered magnesium and calcium reabsorp-
tion. However, it is unclear whether downregulation of
NKCC2 and Na-K-ATPase downregulation in cortex in
protocol 1 resulted mainly from gentamicin toxicity or was
mainly mediated by the influence of a strongly activated
CaSR. Previous studies localized the CaSR also to the base of
the apical brush-border membranes in the PT.27 In addition,
a recent study in opossum kidney (OK) cells (a PT cell line)
and CaSR-transfected HEK-293 cells suggests that over-
stimulation of the CaSR may contribute to AGA toxicity.57
Immunohistochemistry in the present study shows CaSR
protein expression exclusively in cortical and medullary TAL.
However, this finding cannot exclude the localization and the
functional role of CaSR in the PT and further studies are
needed to establish this.
Conclusion
In gentamicin-treated rats (low dose of 40 mg/kg/day), the
selective decrease in the expression of NKCC2 in the TAL
may play a role for the urinary concentrating defect. As
NKCC2 plays an important role in the reabsorption of
sodium and maintaining the lumen-positive voltage in TAL,
which is the driving force for passive magnesium and calcium
reabsorption, the decreased NKCC2 expression following
gentamicin treatment is likely to play a major role for the
development of hypermagnesiuria and hypercalciuria. This is
consistent with the clinically and experimentally observed
renal waste of magnesium and calcium in response to
furosemide treatment.
MATERIALS AND METHODS
Experimental protocols
The animal protocols have been approved by the boards of the
Institute of Anatomy and Institute of Clinical Medicine, University
of Aarhus according to the licenses for use of experimental animals
issued by the Danish Ministry of Justice.
Protocol 1. Experiments were performed using male
Hannover–Wistar rats (225–226 g, Møllegard Breeding Centre, Ry,
Denmark). Starting with day 1, gentamicin (n¼ 10) was injected
once a day intramuscularly over 7 days (1 80 mg/kg body weight/
day, Hexamycin, Durascan Medical Products A/S, Odense,
Denmark, Vnr. 089540). Control rats (n¼ 7) received vehicle alone
(i.e., sterile 0.9% saline, intramuscularly). The rats were maintained
on a standard rodent diet (Altromin No. 1324, Lage, Germany) and
allowed free access to drinking water at all times. In the control
group, rats were offered the amount of food corresponding to the
mean intake of food consumed by gentamicin-treated rats during
the previous day (pair-feeding). Thus, the food intake was matched
between the two groups. The rats were maintained in metabolic
cages during the entire experiment to determine 24 h urine
output, water and food intake, and to allow urine collections for
the measurements of Naþ , Kþ , Cl, PO4
3, Mg2þ , total Ca2þ ,
creatinine, urea, osmolality, and glucose. The body weights were
monitored. The rats were killed for immunoblotting and immuno-
histochemical studies 7 days after start of gentamicin treatment. The
rats were anesthetized with isoflurane (Forane; Abbott Laboratories,
Gentofte, Denmark) and a large laparotomy was made. Blood was
collected from the inferior vena cava and analyzed for Naþ , Kþ ,
Cl, PO4
3, Mg2þ , total Ca2þ , creatinine, urea, and osmolality. The
right kidney was rapidly removed, dissected into zones cortex and
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outer stripe of the outer medulla combined (cortex), ISOM, and
inner medulla and processed for immunoblotting as described below.
The left kidney was fixed by retrograde perfusion as described below.
Protocol 2. Another set of gentamicin-treated rats (n¼ 10) and
control rats (n¼ 7) was made. In this protocol, the experimental
settings were identical to protocol 1, except that gentamicin-treated
rats were injected with a lower dose of gentamicin (1 40 mg/kg
body weight/day, Hexamycin, Durascan Medical Products A/S, Vnr.
089540). Control rats (n¼ 7) received vehicle alone (i.e. sterile 0.9%
saline, intramuscularly).
Clearance studies and urine glucose measurements
Clearance studies were performed over the last 24 h in protocol 1 and
protocol 2. At the last day of each protocol, under isoflurane
anesthesia, 2 ml of blood was collected into a heparinized tube
for determination of plasma electrolytes and osmolality before the rats
were killed. The plasma concentrations of sodium, potassium,
magnesium, total calcium, and creatinine, and the urinary concentra-
tion of creatinine were determined (Vitros 950, Johnson & Johnson,
Raritan, NJ, USA). The concentrations of urinary sodium, potassium,
total calcium, and magnesium were determined by standard flame
photometry (Eppendorf FCM6341, Eppendorf-Netheler-Hinz GmbH,
Hamburg, Germany). The osmolality of the urine and plasma was
determined by freezing-point depression (Advanced Osmometer,
model 3900, Advanced Instruments, Norwood, MA, USA, and
Osmomat 030-D, Gonotec, Berlin, Germany). Glucose levels in the
urine were determined using a qualitative assessment by use of
Multistix (Bayer, Bayer Denmark, Lyngby, Denmark).
Semiquantitative immunoblotting
The dissected renal cortex (which contains tissue from cortex and
the outer stripe of the outer medulla), ISOM, and inner medulla
were homogenized (Ultra-Turrax T8 homogenizer, IKA Labortech-
nik, Staufen, Germany) in ice-cold isolation solution containing
0.3 M sucrose, 25 mM imidazole, 1 mM ethylene diaminetetraacetic
acid, 8.5 mM leupeptin, 1 mM phenylmethylsulfonyl fluoride, with pH
7.2. The homogenates were centrifuged at 4000 g for 15 min at 41C
to remove whole cells, nuclei, and mitochondria, the supernatant
was pipetted off and kept on ice. The total protein concentration was
measured (Pierce BCA protein assay reagent kit, Pierce, Rockford,
IL, USA). All samples were adjusted with isolation solution to reach
the same final protein concentrations and solubilized at 651C for
15 min in sodium dodecyl sulfate-containing sample buffer, and
then stored at 201C. To confirm equal loading of protein, an initial
gel was stained with Coomassie blue. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis was performed on 9 or 12%
polyacrylamide gels. The proteins were transferred by gel electro-
phoresis (BioRad Mini Protean II, Bio-Rad Laboratories GmbH,
Mu¨nchen, Germany) onto nitrocellulose membranes (Hybond ECL
RPN3032D, Amersham Pharmacia Biotech, Little Chalfont, UK).
The blots were subsequently blocked with 5% milk in PBS-T (80 mM
Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1% Tween 20, pH 7.5)
for 1 h and incubated overnight at 41C with primary antibodies. The
sites of antibody–antigen reaction were visualized with horseradish
peroxidase-conjugated secondary antibodies (P447 or P448, diluted
1:3000; DAKO, Glostrup, Denmark) with an enhanced chemilumi-
nescence system (ECL or ECLþ plus) and exposure to photographic
film (Hyperfilm ECL, Amersham Pharmacia Biotech, Little
Chalfont, UK). To estimate the correct band size, we used a
molecular weight marker (Precision Plus Protein Standards, All
Blue, Catalog No. 161–0373, BioRad). The band densities were
quantitated by scanning the films and normalizing the densitometric
values. Results are presented as the relative abundances between the
groups. ECL films with bands within the linear range were scanned
using an AGFA scanner (ARCUS II). The labeling density was
corrected by densitometry of Coomassie-stained gels run in parallel
to the blotted gels.
Immunohistochemistry
A perfusion needle was inserted into the abdominal aorta of
anesthetized rats and the vena cava was cut to establish an outlet.
Blood was flushed from the kidneys with cold phosphate-buffered
saline (PBS) (pH 7.4) for 15 s before switching to cold 3%
paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4) for 3 min.
The kidney was removed and sectioned into 2–3 mm transverse
sections and immersion fixed for additional 1 h, followed by
3 10 min washes with 0.1 M cacodylate buffer of pH 7.4. The
tissue was dehydrated in graded ethanol and left overnight in xylene.
After embedding in paraffin, 2 mm sections of the tissue were cut on
a rotary microtome (Leica Microsystems A/S, Herlev, Denmark).
The sections were de-waxed with xylene and rehydrated with
graded ethanol. Sections had endogenous peroxidase activity
blocked with 0.5% H2O2 in absolute methanol for 10 min. In a
microwave oven, the sections were boiled in target retrieval solu-
tion (1 mmol/l Tris, pH 9.0, with 0.5 mM ethylene glycol-bis
(b-aminoethyl ether)) for 10 min. After cooling, nonspecific binding
was blocked with 50 mM NH4Cl in PBS for 30 min followed by
3 10 min with PBS blocking-buffer containing 1% bovine serum
albumin, 0.05% saponin, and 0.2% gelatin. The sections were
incubated with primary antibody (diluted in PBS with 0.1% bovine
serum albumin and 0.3% Triton X-100) overnight at 41C. The
sections were washed 3 10 min with PBS wash-buffer containing
0.1% bovine serum albumin, 0.05% saponin, and 0.2% gelatin and
incubated with horseradish peroxidase-conjugated secondary anti-
body (goat anti-rabbit immunoglobulin, DAKO A/S, Glostrup,
Denmark) for 1 h at room temperature. After 3 10 min rinses with
PBS wash-buffer, the sites with antibody–antigen reaction were
visualized with a brown chromogen produced within 10 min
by incubation with 0.05% 3,30-diaminobenzidine tetrachloride
(Kem-en Tek, Copenhagen, Denmark) dissolved in distilled water
with 0.1% H2O2. Mayer’s hematoxylin was used for counterstaining
and after dehydration coverslips were mounted with hydro-
phobic medium (Eukitt, O Kindler GmbH & Co, Freiburg,
Germany). Light microscopy was carried out with Leica DMRE
(Leica Microsystems A/S, Herlev, Denmark). All the sections from
the control and experimental group were processed and immuno-
labeled simultaneously.
Primary antibodies
Previously well-characterized rabbit polyclonal antibodies against
the following renal sodium transporters were utilized: the NHE3,58
the NKCC2 (BSC-1),59 the thiazide-sensitive NCC (TSC),20 and
the ENaC subunits a-ENaC, b-ENaC, and g-ENaC.60 A mouse
monoclonal antibody against CaSR was used.61 A mouse mono-
clonal antibody against the Na-K-ATPase a1-subunit was kindly
provided by Dr DM Fambrough, Johns Hopkins University Medical
School.
Statistical analyses
Values were presented as means7standard errors. Comparisons
between two groups were made by unpaired t-test. P-values o0.05
were considered significant.
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